None of the 29 investors followed here reported a position in NIKI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NIKI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for NIKI.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.7 | -17.6 | 2.1 | 9.9 | 17.7 | -24.1 | 26.2 | -30.5 | -28.6 | -46.4 | −75.2% | ||
| 2025 | -58.6 | -18.1 | -11.6 | 11.8 | -2.0 | -1.1 | 70.3 | 27.1 | 2.5 | -28.7 | -6.2 | -21.5 | −62.1% |
| 2024 | -31.4 | -1.8 | 475.5 | -44.7 | -5.1 | -12.0 | -24.7 | -9.4 | -39.8 | -20.6 | -54.5 | 330.8 | +14.3% |
| 2023 | -9.1 | -34.4 | -18.2 | -5.7 | 24.1 | -14.0 | -25.9 | 8.0 | 4.9 | -24.9 | -0.6 | 44.9 | −55.5% |
| 2022 | 17.3 | -18.2 | 16.0 | -37.7 | 21.2 | 8.7 | 4.4 | 7.0 | -24.8 | -44.8 | -12.6 | -0.9 | −63.3% |
| 2021 | 29.6 | -4.1 | -2.9 | -11.4 | 6.1 | 14.1 | -19.6 | 3.5 | -3.8 | -5.5 | -21.9 | -20.6 | −39.3% |
| 2020 | -8.3 | -58.7 | -39.2 | -5.2 | -11.0 | 23.1 | 0.0 | -46.4 | 32.0 | -21.6 | 25.7 | -6.4 | −84.4% |
| 2019 | 0.1 | -2.9 | -8.7 | 6.1 | 121.3 | -20.5 | -13.0 | -24.5 | 0.1 | -3.8 | -2.6 | 2.4 | +4.4% |
| 2018 | — |
No analyst coverage for this instrument.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.